Review Article

Volume – 1, Issue-1, 2025
Journal home Page: https://farpublisher.com/farjams/
Page: 27-33
Publication Month: Feb.2025

Chronic Pain Management in HIV-Positive Sickle Cell Patients: A Comprehensive Review

By
Emmanuel Ifeanyi Obeagu[1] and Francisca Ifeoma Osunwanne[2]
[1]Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, ORCID: 0000-0002-4538-0161
[2]Department of Nursing Science, Faculty of Health Sciences, Imo State University, Owerri, Imo State, Nigeria.

Abstract
Chronic pain is a significant and persistent issue for individuals with sickle cell disease (SCD), often caused by recurrent vaso-occlusive crises (VOC), which lead to tissue ischemia and inflammation. For patients co-infected with HIV, the management of chronic pain becomes even more complex due to the additional complications of HIV-related immune dysfunction, neuropathy, and the effects of antiretroviral therapy (ART). This review explores the challenges of managing chronic pain in HIV-positive sickle cell patients, focusing on the interactions between the two diseases and the impact of ART on pain management strategies. The article discusses the pathophysiology of pain in co-infected individuals, the difficulties in choosing appropriate analgesic regimens, and the importance of individualized treatment approaches. The presence of both HIV and SCD in a single patient leads to overlapping pain mechanisms. In SCD, pain is primarily due to ischemia and infarction from sickle-shaped red blood cells, while HIV-related neuropathy further exacerbates pain. Additionally, ART, though essential for viral suppression, can influence pain by contributing to peripheral neuropathy or affecting the effectiveness of analgesic medications. Opioid use, a common strategy for severe pain management in SCD, is complicated in HIV-positive patients due to potential drug interactions with ART, as well as concerns about misuse and opioid-induced hyperalgesia. Thus, managing pain in this population requires careful balancing of treatment options.
Keywords: *Chronic Pain, HIV, Sickle Cell Disease, Pain Management, Co-infection*

Introduction

Chronic pain is one of the most common and disabling symptoms in individuals with sickle cell disease (SCD), a genetic disorder that primarily affects African, Mediterranean, and Middle Eastern populations. SCD is characterized by the presence of sickle-shaped red blood cells, which have an abnormal shape and are less flexible than normal red blood cells. This abnormality leads to occlusion of small blood vessels, causing episodes of ischemia, infarction, and acute pain, commonly referred to as vaso-occlusive crises (VOC). Over time, recurrent VOCs contribute to the development of chronic pain, which significantly impacts the quality of life, leading to physical limitations, psychological distress, and frequent healthcare utilization.[1-2] The challenge of managing chronic pain in individuals with SCD is compounded when the patient is also HIV-positive. HIV, the virus responsible for acquired immunodeficiency syndrome (AIDS), weakens the immune system by attacking and depleting CD4+ T cells, making individuals more susceptible to infections and other complications. HIV-related neuropathy, which can result from the virus itself or as a side effect of antiretroviral therapy (ART), adds another layer of complexity to pain management. This dual burden of HIV and SCD creates a unique pain management challenge, as the pathophysiology of each disease involves distinct mechanisms of pain generation, and these mechanisms may interact in unpredictable ways.[3-5] While antiretroviral therapy (ART) has dramatically improved the prognosis of HIV-positive individuals, it can also influence pain perceptions and exacerbate existing pain. ART is essential for controlling viral replication and preventing HIV-related complications. However, certain ART drugs, particularly protease inhibitors (PIs) and nucleoside reverse transcriptase Inhibitors (NRTIs), are associated with peripheral neuropathy, a condition that worsens pain symptoms in individuals already suffering from chronic pain due to SCD. Furthermore, the use of ART medications can complicate the management of pain by affecting the pharmacokinetics of pain medications, potentially altering their efficacy and safety profiles.[6]

The pharmacologic management of chronic pain in HIV-positive SCD patients often involves opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and adjuvant such as anticonvulsants and antidepressants. While opioids are effective for managing severe pain, their use is complicated by the risk of opioid use disorder (OUD), which is heightened in individuals with chronic pain, particularly in those with co-occurring HIV and SCD. Additionally, the long-term use of opioids can lead to opioid-induced hyperalgesia, a phenomenon in which chronic opioid use paradoxically increases pain sensitivity. Given these concerns, healthcare providers must carefully balance the need for effective pain relief with the potential risks associated with opioid use, all while considering the impact of ART on drug metabolism.[7-8] In addition to pharmacologic treatments, non-pharmacologic interventions such as physical therapy, cognitive-behavioral therapy (CBT), and complementary therapies are important components of pain management for HIV-positive SCD patients. These therapies aim to address the psychological and functional aspects of chronic pain, which are often overlooked in traditional pain management strategies. CBT has been shown to be effective in helping patients develop coping mechanisms and reduce

pain-related distress, while physical therapy can improve mobility and reduce pain exacerbated by physical deconditioning. Complementary therapies, such as acupuncture and massage, have also been reported to provide relief in some patients, although further research is needed to establish their efficacy.[9-11] The complexity of chronic pain in HIV-positive SCD patients underscores the need for a personalized, multidisciplinary approach to care. Pain management in this population must consider the unique interactions between HIV, SCD, and ART, as well as the patient's individual pain profile, medical history, and psychosocial factors. Clinicians must collaborate across specialties to develop treatment plans that address all aspects of the patient's pain, including physical, emotional, and psychological dimensions. Given the high risk of complications and the multifaceted nature of chronic pain in this population, ongoing monitoring and adjustment of treatment strategies are essential to optimizing care and improving patient outcomes.[12-13]

Path physiology of Chronic Pain in HIV-Positive Sickle Cell Patients

Chronic pain in individuals with sickle cell disease (SCD) arises from the complex interplay of vascular occlusion, ischemia, and tissue damage due to the sickling of red blood cells. In patients with HIV, the path physiology becomes even more intricate due to the additional impact of HIV-related neuropathy, immune dysfunction, and the effects of antiretroviral therapy (ART). [14] In SCD, the hallmark feature is the sickling of red blood cells under low oxygen conditions, which leads to the blockage of small blood vessels, resulting in ischemia and subsequent tissue injury. This blockage causes vaso-occlusive crises (VOC), a painful condition characterized by severe and acute pain episodes that are often recurrent. Over time, repeated VOCs contribute to the development of chronic pain through the accumulation of irreversible tissue damage, including infarctions and fibrosis. The pain experienced by individuals with SCD is largely driven by the inflammatory response triggered by ischemia, which leads to the release of pro-inflammatory mediators such as cytokines, chemokines, and prostaglandins. These inflammatory mediators sensitize nociceptors (pain receptors), exacerbating the pain response.[15] In HIV-positive individuals, the path physiology of pain becomes further complicated by the direct effects of the virus and its treatment. HIV itself can contribute to chronic pain through the development of HIV-associated neuropathy. The virus preferentially targets and depletes CD4+ T cells, which weakens the immune system and predisposes individuals to infections and inflammatory processes. HIV-associated sensory neuropathy is a common complication that results from direct viral damage to peripheral nerves, leading to painful symptoms such as burning, tingling, or sharp sensations. This neuropathic pain is often worsened by ART, particularly with the use of certain classes of drugs such as nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), which have been linked to peripheral neuropathy as a side effect.[16-18]

The concurrent presence of both SCD and HIV in the same individual results in the overlap of these two distinct pain pathways, amplifying the complexity of chronic pain. In HIV-positive SCD patients, the pain from sickle cell crises is often compounded by the neuropathic pain resulting from HIV-related damage to the nervous system. This dual burden of pain can lead to heightened pain sensitivity and more frequent and severe pain episodes. The inflammatory processes that underlie VOCs in SCD may also be exacerbated by HIV-related immune dysfunction, further sensitizing nociceptors and perpetuating the pain cycle. Furthermore, the activation of inflammatory pathways in both SCD and HIV can contribute to the development of central sensitization, a phenomenon in which the nervous system becomes hyper-responsive to stimuli, thereby increasing pain perception.[19-20] ART plays a dual role in this complex pain landscape. While it is essential for managing HIV by suppressing viral replication, ART can also have significant side effects that impact pain perception. As mentioned, certain ART drugs are associated with peripheral neuropathy, which can increase the pain burden in HIV-positive SCD patients. Moreover, ART may interfere with the pharmacokinetics of pain medications, such as opioids, potentially altering their efficacy and safety profiles. Drug-drug interactions between ART and analgesics, such as those mediated by cytochrome P450 enzymes, must be carefully considered to prevent inadequate pain relief or adverse effects. Additionally, ART-induced mitochondrial toxicity associated with certain drugs can contribute to muscle and nerve dysfunction, potentially exacerbating pain.[21-23]

Challenges in Pain Management for HIV-Positive Sickle Cell Patients

Managing chronic pain in HIV-positive sickle cell disease (SCD) patients presents significant challenges due to the interplay of multiple factors, including the complex path physiology of both diseases, the side effects of antiretroviral therapy (ART), and the psychological burden of living with two chronic, debilitating conditions. These challenges necessitate a comprehensive and individualized approach to pain management that addresses both the physical and psychosocial aspects of pain, while also navigating potential medication-related complications.[24] One of the primary challenges in pain management for HIV-positive SCD patients is the overlapping pain mechanisms from both conditions. In SCD, pain is primarily driven by vaso-occlusive crises (VOC), which cause blockage of small blood vessels, leading to ischemia, inflammation, and tissue damage. The resultant pain is often intense, recurrent, and difficult to manage. For individuals also living with HIV, neuropathy becomes an additional pain source. HIV-associated peripheral neuropathy is a common complication, which manifests as burning, tingling, or sharp pain, often in the limbs. The presence of both inflammatory and neuropathic pain creates a more complex pain profile, making it harder to identify the most appropriate treatment strategies.[25-26] The use of opioids is a common approach to managing severe pain in patients with SCD, but it presents challenges, especially for HIV-positive patients. Opioids are effective for managing acute pain, but long-term use carries the risk of opioid use disorder (OUD), particularly in individuals who are also coping with the chronic nature of

both SCD and HIV. The concern is heightened by the potential for misuse, dependency, and opioid-induced hyperalgesia, a condition in which prolonged opioid use paradoxically increases pain sensitivity. Furthermore, drug interactions between opioids and ART can complicate their use. ART, especially protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NRTIs), can alter the metabolism of opioids and other analgesic medications, potentially reducing their effectiveness or causing adverse effects. Healthcare providers must carefully balance the need for pain relief with the risks associated with opioid use, all while considering the potential for ART-drug interactions.[27-29]

Another significant challenge is the potential impact of ART on pain management. While ART is essential for controlling HIV replication, certain ART medications are associated with peripheral neuropathy, which can exacerbate pain in individuals with HIV and SCD. The neurotoxic effects of ART drugs, particularly PIs and NRTIs, are well-documented, and this neuropathy can contribute to a heightened pain experience. The presence of ART-related neuropathy complicates the choice of pain management strategies, as many pain relief options, including certain medications like anticonvulsants or antidepressants, may have limited efficacy in addressing this type of pain. Additionally, ART can affect the pharmacokinetics of various analgesics, leading to concerns about drug interactions and the need for dose adjustments. These factors highlight the importance of closely monitoring patients and tailoring pain management regimens based on their unique needs and the specific ART regimen they are on.[30-32]

Psychosocial factors further complicate pain management in HIV-positive SCD patients. Chronic pain can lead to depression, anxiety, and other mental health issues, which are common among individuals with both SCD and HIV. These psychological burdens can worsen pain perception, as well as hinder patients' ability to adhere to prescribed pain management regimens. Additionally, stigma surrounding both HIV and SCD can contribute to feelings of isolation, low self-esteem, and reluctance to seek help. The stigma associated with HIV, in particular, can lead to delays in diagnosis, treatment initiation, and access to care, thereby exacerbating pain and further complicating management efforts. Furthermore, the emotional toll of managing two chronic conditions can lead to non-compliance with both pain management and ART regimens, affecting overall health outcomes.[33-34]

Non-pharmacologic interventions are essential in addressing these challenges, but they also present barriers to effective implementation. Physical therapy, cognitive-behavioral therapy (CBT), and complementary therapies such as acupuncture or massage can be beneficial in managing chronic pain, particularly by addressing the psychological and functional aspects of pain. However, access to these therapies may be limited due to financial constraints, availability of trained professionals, and healthcare system limitations. Moreover, the integration of non-pharmacologic treatments into routine care requires time, resources, and patient buy-in, which can be difficult for those who are already overwhelmed by the demands of managing multiple health conditions.[35-36] Finally, there is a need for improved coordination between healthcare providers to optimize pain management in this population. Given the complex nature of chronic pain in HIV-positive SCD patients, a multidisciplinary approach is crucial. Hematologists, HIV specialists, pain management teams, and mental health professionals must work together to develop individualized treatment plans that address the unique challenges faced by these patients. This requires not only a comprehensive understanding of the underlying diseases but also an awareness of the specific barriers to pain management and how they can be overcome. Additionally, ongoing monitoring and adjustment of treatment plans are necessary to ensure that pain is effectively managed without introducing harmful side effects or complications.[37]

Therapeutic Approaches in Pain Management for HIV-Positive Sickle Cell Patients

Managing chronic pain in HIV-positive sickle cell disease (SCD) patients requires a tailored, multi-disciplinary approach that addresses both the underlying path physiology of pain and the unique challenges posed by the dual presence of HIV and SCD. These patients often experience pain from both sickle cell-related vaso-occlusive crises (VOC) and HIV-associated neuropathy, creating a complex pain management scenario. Therapeutic approaches for pain management must take into account the interactions between these two conditions, the effects of antiretroviral therapy (ART), and the potential for complications from pharmacologic treatments. This section reviews the key therapeutic strategies for effectively managing chronic pain in HIV-positive SCD patients.[38]

Pharmacologic Approaches

Pharmacologic interventions form the cornerstone of pain management in HIV-positive SCD patients. The choice of analgesics depends on the severity and type of pain, as well as the individual patient's medical history and response to treatment. In patients with severe, acute pain due to vaso-occlusive crises, opioids are often prescribed for their potent analgesic effects. However, the use of opioids in this population requires careful monitoring due to concerns over the risk of opioid use disorder (OUD), opioid-induced hyperalgesia, and potential interactions with ART. Certain ART medications, particularly protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), can alter the metabolism of opioids, necessitating dose adjustments and careful monitoring to avoid either under-treatment or overdose.[39] In addition to opioids, non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen are often used to manage mild-to-moderate pain associated with sickle cell crises. However, NSAIDs must be used cautiously in HIV-positive patients, as they can increase the risk of gastrointestinal bleeding and kidney toxicity, especially in those with compromised immune function or concurrent comorbidities. Adjuvants, such as anticonvulsants (e.g., gabapentin) and antidepressants (e.g., amitriptyline), can be effective in managing neuropathic pain caused by HIV-associated neuropathy. These medications work by modifying central nervous system activity to reduce pain signaling and improve pain tolerance. While these agents are often beneficial, side effects such as

sedation, dizziness, and weight gain can limit their use in some patients.[40]

Non-Pharmacologic Approaches

Non-pharmacologic interventions play an important role in managing chronic pain in HIV-positive SCD patients by addressing the psychological, functional, and emotional aspects of pain. Cognitive-behavioral therapy (CBT) is one of the most well-established non-pharmacologic treatments for chronic pain. CBT helps patients develop coping strategies to manage pain and improve quality of life. It involves identifying negative thought patterns associated with pain and replacing them with more adaptive, positive coping mechanisms. Research has shown that CBT can reduce pain intensity and improve mood in patients with chronic pain, including those with HIV and SCD. Similarly, relaxation techniques such as mindfulness meditation, guided imagery, and deep-breathing exercises have been shown to help reduce pain perception by lowering stress and anxiety, which can exacerbate pain symptoms.[41] Physical therapy is another key component of non-pharmacologic pain management. In patients with SCD, chronic pain is often associated with musculoskeletal deconditioning, which can exacerbate pain and limit mobility. Physical therapy aims to improve strength, flexibility, and function, thereby reducing pain and enhancing overall quality of life. Gentle exercise programs, including stretching, strengthening exercises, and low-impact aerobic activities, can improve blood circulation and reduce the frequency and severity of pain episodes. For HIV-positive SCD patients with peripheral neuropathy, physical therapy can also help mitigate the impact of nerve damage on movement and function, ultimately contributing to pain relief.[42]

Complementary and Alternative Therapies

Complementary and alternative therapies, such as acupuncture, massage, and chiropractic care, have also been investigated as adjuncts to traditional pain management approaches. These therapies may help alleviate pain by promoting relaxation, improving blood flow, and enhancing the release of natural pain-relieving endorphins. While the evidence supporting the use of acupuncture and massage in chronic pain management remains mixed, some patients report significant improvements in pain relief and overall well-being. Acupuncture, in particular, has been found to reduce pain intensity in various chronic pain conditions by stimulating specific points on the body that correspond to pain pathways. Additionally, massage therapy can reduce muscle tension, improve circulation, and promote relaxation, providing relief from both the musculoskeletal pain associated with SCD and the neuropathic pain seen in HIV-positive individuals.[43]

Multidisciplinary Approach

A multidisciplinary approach is essential for managing chronic pain in HIV-positive SCD patients. Pain management for these individuals should involve a team of healthcare professionals, including pain specialists, hematologists, infectious disease experts, psychologists, physical therapists, and social workers. This collaborative approach allows for comprehensive care that addresses all aspects of the patient's pain, including its physical, emotional, and psychological components. The team can work together to optimize treatment plans, monitor for potential complications, and adjust therapies based on the patient's evolving needs. Additionally, involving mental health professionals in pain management is critical, as chronic pain often leads to anxiety, depression, and other mood disorders that can exacerbate pain perception.[44]

Personalized Pain Management

Given the complexity of managing chronic pain in HIV-positive SCD patients, personalized care is essential. Treatment plans must be tailored to each patient, taking into account their pain severity, medical history, treatment preferences, and response to previous interventions. This personalized approach ensures that the patient receives the most effective and safest pain management, with minimal side effects and complications. Clinicians must also be vigilant in monitoring for potential drug interactions, particularly between analgesics and ART medications, to prevent adverse outcomes. Ongoing assessment and adjustment of treatment strategies are key to providing optimal care, as pain management is often dynamic and may require changes over time.[45]

The Role of Multi-Disciplinary Care and Individualized Treatment in Chronic Pain Management for HIV-Positive Sickle Cell Patients

Chronic pain management in HIV-positive sickle cell disease (SCD) patients is complex and requires a holistic, individualized approach that takes into account the multifaceted nature of the pain, its underlying causes, and the patient's unique circumstances. Multi-disciplinary care, which involves collaboration among various healthcare providers, is crucial in addressing the various dimensions of chronic pain. This approach ensures comprehensive treatment that incorporates both pharmacologic and non-pharmacologic interventions, as well as psychological and social support, to improve patient outcomes. Moreover, individualized treatment is essential, as each patient's experience with pain and response to therapies can vary greatly.

Multi-Disciplinary Care Approach

The multi-disciplinary care model is integral to effectively managing chronic pain in HIV-positive SCD patients. The team typically consists of pain specialists, hematologists, infectious disease experts, physical therapists, psychologists, social workers, and other healthcare professionals. Each specialist brings a unique perspective and skillset to address the diverse factors that contribute to pain, including vascular occlusion, neuropathy, inflammation, and psychological distress. This collaborative model allows for a more comprehensive understanding of the patient's condition and the formulation of an optimal treatment plan. Pain specialists, for example, focus on the pharmacologic management of pain and can provide expertise in managing complex analgesic regimens. Hematologists are critical in managing the sickle cell disease component, monitoring the frequency of vaso-occlusive crises, and optimizing treatments such as hydroxyurea or blood transfusions. Infectious disease specialists play a pivotal role in managing HIV and the complications arising from the virus or its treatment, ensuring that antiretroviral therapy (ART) is optimized for the patient. Physical therapists can assist with

mobility, functional restoration, and musculoskeletal pain associated with SCD and neuropathic pain linked to HIV. Psychological support, provided by counselors or psychologists, helps address the emotional and mental health challenges of chronic pain, such as depression, anxiety, and the stress of living with multiple chronic conditions.[46]

Individualized Treatment Plans

An individualized treatment approach is crucial in chronic pain management for HIV-positive SCD patients due to the unique and dynamic nature of each patient's pain experience. Factors such as the severity of sickle cell disease, the extent of HIV-related neuropathy, the presence of co-morbidities, and the patient's personal preferences all influence the treatment strategy. The optimal approach to pain management must be personalized, ensuring that patients receive the most effective and appropriate interventions tailored to their specific needs. For instance, in patients with significant neuropathic pain from HIV-related neuropathy, medications such as anticonvulsants (gabapentin or pregabalin) or antidepressants (amitriptyline) may be prioritized. On the other hand, in those with predominantly musculoskeletal pain from sickle cell crises, nonsteroidal anti-inflammatory drugs (NSAIDs) or opioids may be more appropriate. A personalized approach also takes into account the patient's response to ART, as some drugs may exacerbate neuropathic pain or have interactions with pain medications. Adjustments in ART and analgesic regimens are essential to avoid side effects such as peripheral neuropathy, which can worsen pain. In addition to pharmacologic treatments, individualized non-pharmacologic interventions are tailored to each patient's circumstances. A physical therapy regimen can be customized based on the patient's mobility level and pain location, while psychological interventions such as cognitive-behavioral therapy (CBT) may be utilized for patients experiencing emotional distress related to chronic pain. Social support is also an integral part of the individualized treatment plan, addressing the patient's social needs and helping them manage the challenges associated with living with multiple chronic conditions.[47]

Ongoing Assessment and Adjustment

An important aspect of both multi-disciplinary care and individualized treatment is continuous assessment and adjustment of the treatment plan. Chronic pain is dynamic and can change over time due to factors such as disease progression, response to treatment, and the development of new pain sources. Regular follow-ups with the healthcare team are necessary to monitor the effectiveness of pain management strategies, identify any emerging complications, and make necessary adjustments to medications or interventions. For instance, if a patient experiences worsening neuropathic pain despite using anticonvulsants, the treatment plan may need to be altered to incorporate other therapies, such as topical treatments or advanced pain management techniques. Furthermore, as HIV-positive SCD patients may experience multiple comorbidities, close monitoring is necessary to avoid complications such as drug-drug interactions, medication toxicity, or the exacerbation of pre-existing conditions. This ongoing assessment ensures that the pain management plan remains flexible and responsive to the changing needs of the patient. The involvement of the multi-disciplinary team allows for a holistic approach to these adjustments, ensuring that both the physiological and psychosocial aspects of chronic pain are adequately addressed.[48]

Conclusion

Chronic pain in HIV-positive sickle cell disease (SCD) patients presents unique challenges due to the interplay of both conditions and their associated complications. Effective pain management in this population requires a comprehensive, multi-disciplinary approach that takes into account the complex nature of the pain, its underlying causes, and the patient's individual needs. By bringing together experts from various fields, including pain specialists, hematologists, infectious disease specialists, physical therapists, and mental health professionals, healthcare providers can create a holistic treatment plan that addresses both the physical and emotional aspects of chronic pain. Individualized treatment is critical in managing the pain of HIV-positive SCD patients, as each patient's experience with pain and response to therapies varies. A personalized approach allows for tailored interventions, ensuring that the treatment is appropriate and effective for the patient's unique condition. Pharmacologic and non-pharmacologic therapies, alongside psychological and social support, must be carefully selected and monitored to provide the best possible outcomes. Regular assessment and adjustments to the treatment plan are necessary to adapt to changing symptoms, progression of the disease, and response to treatment.

References

1. Owusu ED, Visser BJ, Nagel IM, Mens PF, Grobusch MP. The interaction between sickle cell disease and HIV infection: a systematic review. Clinical Infectious Diseases. 2015; 60(4):612-626.
2. Boateng LA, Ngoma AM, Bates I, Schonewille H. Red blood cell alloimmunization in transfused patients with sickle cell disease in sub-Saharan Africa; a systematic review and meta-analysis. Transfusion Medicine Reviews. 2019; 33(3):162-169.
3. Ola B, Olushola O, Ebenso B, Berghs M. Sickle Cell Disease and Its Psychosocial Burdens in Africa. InSickle Cell Disease in Sub-Saharan Africa 2024: 67-80. Routledge.
4. Makani J, Ofori-Acquah SF, Nnodu O, Wonkam A, Ohene-Frempong K. Sickle cell disease: new opportunities and challenges in Africa. The scientific world journal. 2013; 2013(1):193252.
5. Ochocinski D, Dalal M, Black LV, Carr S, Lew J, Sullivan K, Kissoon N. Life-threatening infectious complications in sickle cell disease: a concise narrative review. Frontiers in Pediatrics. 2020; 8:38.
6. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology, 2024; 2(1): 14-33

7. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
8. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health, 2024; 2 (1): 52-61
9. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024; 10(1):25-36.
10. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Asian J Dental Health Sci, 2024; 4(1):32-7. Available from: http://ajdhs.com/index.php/journal/article/view/62
11. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health, 2024; 2 (1): 52-63
12. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science, 2024; 2(2):1-17
13. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV, 2024; 2(2): 60-73 1
14. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science, 2024; 2(2): 20- 35
15. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIVExposed Infants: A Review. Elite Journal of Immunology, 2024; 2(3): 1-18
16. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. Newport International Journal of Biological and Applied Sciences (NIJBAS) 2023. http://hdl.handle.net/20.500.12493/14626
17. Ntsekhe M, Baker JV. Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context. Circulation. 2023; 147(1):83-100.
18. Obare LM, Temu T, Mallal SA, Wanjalla CN. Inflammation in HIV and its impact on atherosclerotic cardiovascular disease. Circulation research. 2024; 134(11):1515-1545
19. Hmiel L, Zhang S, Obare LM, Santana MA, Wanjalla CN, Titanji BK, Hileman CO, Bagchi S. Inflammatory and immune mechanisms for atherosclerotic cardiovascular disease in HIV. International journal of molecular sciences. 2024; 25(13):7266..
20. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2(3): 10-24
21. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. Elite Journal of Immunology, 2024; 2(2): 15-28
22. Belisário AR, Blatyta PF, Vivanco D, Oliveira CD, Carneiro-Proietti AB, Sabino EC, de Almeida-Neto C, Loureiro P, Máximo C, de Oliveira Garcia Mateos S, Flor-Park MV. Association of HIV infection with clinical and laboratory characteristics of sickle cell disease. BMC Infectious Diseases. 2020; 20(1):638.
23. Bhowmik A, Banerjee P. Hematological manifestation in HIV infected children. J Coll Physicians Surg Pak. 2015; 25(2):119-123.
24. Gill AF, Ahsan MH, Lackner AA, Veazey RS. Hematologic abnormalities associated with simian immunodeficieny virus (SIV) infection mimic those in HIV infection. Journal of Medical Primatology. 2012; 41(3):214-224.
25. Nouraie M, Nekhai S, Gordeuk VR. Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in US hospital discharge records: a cross-sectional study. Sexually transmitted infections. 2012; 88(7):528-533.
26. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine. 2024; 2(1):33-45.
27. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health, 2024; 2 (1): 35-51
28. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 84-99
29. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology, 2024; 2(3): 33-44
30. Obeagu EI, Obeagu, GU. Impact of Blood Transfusion on Viral Load Dynamics in HIVPositive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 42-60
31. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies . Elite Journal of Laboratory Medicine, 2024; 2(2): 30-46
32. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV, 2024; 2(2): 43-59
33. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for

Treatment. Elite Journal of Haematology, 2024; 2(3): 25-41
34. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. Elite Journal of Health Science, 2024; 2(2): 16-29
35. Obeagu EI, Amaeze AA, Ogbu ISI, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science, 2024; 2(2): 33-46
36. Obeagu EI, Obeagu, GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review, 2024; 2(1): 1-16
37. Kibaru EG, Nduati R, Wamalwa D, Kariuki N. Impact of highly active antiretroviral therapy on hematological indices among HIV-1 infected children at Kenyatta National Hospital-Kenya: retrospective study. AIDS research and therapy. 2015; 12:1-8.
38. Enawgaw B, Alem M, Addis Z, Melku M. Determination of hematological and immunological parameters among HIV positive patients taking highly active antiretroviral treatment and treatment naïve in the antiretroviral therapy clinic of Gondar University Hospital, Gondar, Northwest Ethiopia: a comparative cross-sectional study. BMC hematology. 2014; 14:1-7.
39. Gudina A, Wordofa M, Urgessa F. Immuno-hematological parameters among adult HIV patients before and after initiation of Dolutegravir based antiretroviral therapy, Addis Ababa, Ethiopia. Plos one. 2024; 19(10):e0310239.
40. Geletaw T, Tadesse MZ, Demisse AG. Hematologic abnormalities and associated factors among HIV infected children pre-and post-antiretroviral treatment, North West Ethiopia. Journal of blood medicine. 2017:99-105.
41. Jegede FE, Oyeyi TI, Abdulrahman SA, Mbah HA, Badru T, Agbakwuru C, Adedokun O. Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria. PLoS One. 2017; 12(3):e0174233.
42. Obeagu EI, Obeagu GU. ART and Platelet Dynamics: Assessing Implications for HIV Patient Care. Elite Journal of Haematology. 2024; 2(4):68-85.
43. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science. 2024;2(2):5-15.
44. Ciccacci F, Lucaroni F, Latagliata R, Morciano L, Mondlane E, Balama M, Tembo D, Gondwe J, Orlando S, Palombi L, Marazzi MC. Hematologic alterations and early mortality in a cohort of HIV positive African patients. PLoS One. 2020; 15(11):e0242068.
45. Ashenafi G, Tibebu M, Tilahun D, Tsegaye A. Immunohematological Outcome Among Adult HIV Patients Taking Highly Active Antiretroviral Therapy for at Least Six Months in Yabelo Hospital, Borana, Ethiopia. Journal of Blood Medicine. 2023:543-554.
46. Obeagu EI, Goryacheva OG. The Role of Inflammation in HIV and Sickle Cell Disease Co-Morbidity. Lifeline HIV, 2025; 3(1): 1-12
47. Obeagu EI, Goryacheva OG. Oxidative Stress in HIV and Sickle Cell Disease: A Double Burden. Lifeline HIV, 2025; 3(1): 13-24
48. Obeagu EI, Goryacheva OG. HIV and Sickle Cell Disease: A Focus on Liver Dysfunction. Lifeline HIV, 2025; 3(1): 25-40

